{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:59:06Z","timestamp":1778943546073,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T00:00:00Z","timestamp":1139184000000},"content-version":"vor","delay-in-days":2289,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[1999,11]]},"abstract":"<jats:p><jats:bold>ABSTRACT: <\/jats:bold> Hyperglycemia in Type 2 diabetes represents a steady\u2010state re\u2010regulation of plasma glucose to a higher\u2010than\u2010normal level after an overnight fast. The underlying pathophysiology represents an interaction between impaired \u03b2\u2010cell function and peripheral and hepatic insulin resistance which leads to abnormal hepatic glucose production. Subjects with the Metabolic Syndrome are at an increased risk for Type 2 diabetes and often have one or both of these disorders present even when glucose tolerance is normal. Thus, sophisticated measures of \u03b2\u2010cell function and insulin sensitivity demonstrate a high frequency in populations characterized as having a high prevalence of atherosclerosis, central obesity, hypertension, and dyslipidemia with or without impaired glucose tolerance. Hyperglycemia compensates for the impairment of \u03b2\u2010cell function and therefore, in our view, the \u03b2\u2010cell is the critical factor in its development. Hyperinsulinemia, a curvilinear compensation for insulin resistance that is closely correlated with central adiposity, is another important predictor of hyperglycemia. In a Japanese\u2010American population followed for five years, impaired \u03b2\u2010cell function was present at baseline and preceded the accumulation of intraabdominal fat in those who developed Type 2 diabetes five years later. This interaction between these two pathophysiologic abnormalities in this sequence supports the hypothesis that \u03b2\u2010cell dysfunction contributes to the development of central adiposity by reduced CNS insulin signaling.<\/jats:p>","DOI":"10.1111\/j.1749-6632.1999.tb07786.x","type":"journal-article","created":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T16:36:31Z","timestamp":1139243791000},"page":"73-83","source":"Crossref","is-referenced-by-count":30,"title":["Mechanisms for Hyperglycemia in the Metabolic Syndrome: The Key Role of \u03b2\u2010Cell Dysfunction"],"prefix":"10.1111","volume":"892","author":[{"suffix":"Jr.","given":"DANIEL","family":"PORTE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,6]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"Kahn S. E. & D. Porte Jr. 1997. The pathophysiology of type II (noninsulin dependent) diabetes mellitus: implications for treatment.InDiabetes Mellitus. D. Porte Jr. & R. S. Sherwin Eds.: 487\u2010512. Appleton & Lange. Stamford CT."},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.12.1859"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.4.518"},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2337\/diab.46.4.701","article-title":"Predictors of progression from impaired glucose tolerance to NIDDM","volume":"46","author":"Edelstein S. L.","year":"1997","journal-title":"Diabetes"},{"key":"e_1_2_8_6_2","unstructured":"Porte D. Jr. & S. E. Kahn. 1999. Pathophysiology of impaired glucose tolerance. Curr. Opin. Endocrinol. Diabetes. In press."},{"key":"e_1_2_8_7_2","first-page":"247","article-title":"The key role of islet dysfunction in type 2 diabetes mellitus","volume":"18","author":"Porte D.","year":"1995","journal-title":"Clin. Invest. Med."},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.42.11.1663"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110398"},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2337\/diab.35.3.362","article-title":"The insulin sensitivity index in man: correlation between clamp\u2010derived and IVGTT\u2010derived values","volume":"35","author":"Beard J. C.","year":"1986","journal-title":"Diabetes"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/dme.1996.13.s6.25"},{"key":"e_1_2_8_12_2","first-page":"A179","article-title":"Comparison of estimates of insulin sensitivity and B\u2010cell function derived from oral glucose tolerance test versus the intravenous glucose tolerance test and minimal model","volume":"47","author":"Howell W. M.","year":"1998","journal-title":"Diabetes"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201023260104"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117715"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/372186a0"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/372182a0"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81896-6"},{"key":"e_1_2_8_18_2","first-page":"30253","article-title":"Pancreatic beta\u2010cell\u2010specific targeted disruption of glucokinase gene","volume":"270","author":"Terauchi Y.","year":"1995","journal-title":"Diabetes mellitus due to defective insulin secretion to glucose. J. Biol. Chem."},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1994.tb00076.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(94)90226-7"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.45.4.422"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.6.747"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051002"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.5.1571"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115274"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.4.1399"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.38.11.1333"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.2.241"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.1999.tb07786.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.1999.tb07786.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:15:41Z","timestamp":1695629741000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.1999.tb07786.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,11]]}},"alternative-id":["10.1111\/j.1749-6632.1999.tb07786.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb07786.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,11]]}}}